title: Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.
abstract: Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.
authors.affiliation: Department of Medical Oncology, Cancer Research Campaign, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M204BX, UK. malcolm.ransom@man.ac.uk
authors.forename: M R
authors.initials: MR
authors.lastname: Ranson
authors.forename: S
authors.initials: S
authors.lastname: Cheeseman
authors.forename: S
authors.initials: S
authors.lastname: White
authors.forename: J
authors.initials: J
authors.lastname: Margison
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008081:Liposomes
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D004317:Doxorubicin